Results 61 to 70 of about 2,401 (204)

Characterizing treatment initiation with central nervous system–active polypharmacy among adults with dementia

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Central nervous system (CNS) –active polypharmacy, defined as concurrent use of antidepressants, antipsychotics, anti‐seizure medications, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, opioids, or skeletal muscle relaxants for ≥ 31 consecutive days, poses significant risks patients with dementia.
Donovan T. Maust, Rachel C. Davis, Julie Strominger, Steven C. Marcus, Hyungjin Myra Kim, Tanner Caverly, Frederic C. Blow, Lauren P. Wallner, Sarah Krein, Sarah E. Vordenberg   +9 more
wiley   +1 more source

Social and Clinical Factors Associated With Antipsychotic Medication Discontinuation in Patients With Schizophrenia

International Journal of Methods in Psychiatric Research, Volume 35, Issue 2, June 2026.
ABSTRACT Objectives This study aims to identify social and clinical factors associated with antipsychotic medication discontinuation in patients with schizophrenia. Methods This cross‐sectional case‐control study comprised 111 schizophrenia patients, including 55 who discontinued medication on their own initiative and 56 matched continuous‐treatment ...
Zhengquan Chen, Yiming Wu, Zuowei Wang, Jun Wang, Chao Jiang, Wenchao Shen, Yanting Zheng, Yi Wu   +7 more
wiley   +1 more source

Cariprazine, A Dopamine D2/D3 Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer [PDF]

, 2018
Multidrug resistance (MDR) is a continuing clinical problem that limits the efficacy of chemotherapy in cancer. The over expression of the ATP-binding cassette (ABC) family G2 (ABCG2) transporter is one of the main mechanisms that mediates MDR in cancer.
Noor Hussein, Haneen Amawi, Chandrabose Karthikeyan, Angelique Nyinawabera, Atul Vij, Charles R. Ashby, Amit K. Tiwari, Vishwa M. Khare   +7 more
core   +1 more source

Efficacy and safety of cariprazine in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials [PDF]

, 2020
Background: Cariprazine is a new atypical antipsychotic drug approved for the treatment of schizophrenia and bipolar disorders. Methods: we searched the published randomized controlled-trials (RCT) to review cariprazine efficacy and tolerability using ...
Antoun Reyad, Ayman, Ayman Antoun Reyad, Cooper, Hannah, Mishriky, Raafat, Hannah Cooper, Raafat Mishriky   +5 more
core   +4 more sources

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine

Drug Design, Development and Therapy, 2019
Béla Kiss, Zsolt Némethy, Károly Fazekas, Dalma Kurkó, István Gyertyán, Katalin Sághy, István Laszlovszky, Bence Farkas, Norbert Kirschner, Etelka Bolf-Terjéki, Ottilia Balázs, Bal ...
Kiss B, Némethy Z, Fazekas K, Kurkó D, Gyertyán I, Sághy K, Laszlovszky I, Farkas B, Kirschner N, Bolf-Terjéki E, Balázs O, Lendvai B   +11 more
doaj  

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies

Neuropsychiatric Disease and Treatment, 2021
Ágota Barabássy,1 Barbara Sebe,1 Károly Acsai,1 István Laszlovszky,1 Balázs Szatmári,1 Willie R Earley,2 György Németh1 1Medical Division, Gedeon Richter Plc, Budapest, Hungary; 2Clinical Development,
Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G   +6 more
doaj  

Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting

Frontiers in Psychiatry, 2023
Real-world evidence fills in an important gap by providing data on the effectiveness and tolerability of new medications in everyday patients. In this data collection form a Spanish hospital, the effectiveness and tolerability of cariprazine were ...
Lluis Niell Galmes, Elmars Rancans
doaj   +1 more source

Pharmacological Management, Safety, and Outcomes in Bipolar Disorder: An Integrated Narrative Review of Clinical and Translational Evidence

Neuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.
This graph summarizes bipolar disorder management, showing pharmacological treatments including lithium, valproate, antipsychotics, combination therapy, and emerging agents. It links these treatments to outcomes such as relapse reduction, mortality benefits, and cognitive effects, while highlighting safety issues, poor adherence, pregnancy risks, and ...
Gudisa Bereda
wiley   +1 more source

Cariprazine in Bipolar Depression and Mania: State of the Art. [PDF]

, 2018
BACKGROUND & OBJECTIVE: Cariprazine is a piprazine derivative approved by the FDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. High affinity for D3 dopamine receptors and observed actions on 5HT1A, 5HT2A
Janiri L, Romano, Benedetta, Carocci, Valentina, Mazza M   +3 more
core   +1 more source

Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
This graphical summary illustrates the efficacy and safety of brexpiprazole (2–4 mg) in patients with schizophrenia. The meta‐analysis demonstrates significant improvement in clinical outcomes, with reductions in Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression ‐ Severity scale (CGI‐S) scores, indicating better symptom ...
Sher Bano, Aashan Ahmad, Abdul Haseeb Mohammed, Ismailova Rushana Nurbekovna, Saja Saad, Noor Fatima, Muhammad Bilal Akbar, Zainab Salahuddin, Sadikun Nabi, Mohammad Mustafa Ababneh, Laiba Ajmal, Sidra Hariss, Hiba Manaf, Farah Saleh, Raouf Khan   +14 more
wiley   +1 more source